https://www.selleckchem.com/products/a-769662.html
PROSPERO registration ID CRD42020151106. The implications of molecular biomarkers 1/2 mutations and gene promoter methylation were evaluated for prognostic outcome of glioma patients. Glioma cases were analyzed for 1/2 mutations and promoter methylation by DNA sequencing and methylation-specific PCR, respectively. Mutations found in 1/2 genes totaled 63.4% (N=4 wherein 1 mutations were significantly associated with oligidendrioglioma (p=0.005) and astrocytoma (p=0.0002). 1 mutants presented more, 60.5% in promoter-methylated cases (p
Like
Comment
Share
